Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis

Jian Wen Chen, Michael F. Nielsen, Andrea Caumo, Hendrik Vilstrup, Jens Sandahl Christiansen, Jan Frystyk

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Liver cirrhosis is characterized by reduced circulating IGF-I and this has been linked to an adverse clinical outcome. Therefore, we investigated the dynamic changes in circulating total, free, and bioactive IGF-I, IGF-binding protein (IGFBP)-1, IGFBP-2, and IGFBP-1-bound IGF-I (binary complex) during an oral glucose tolerance test (OGTT) in patients with liver cirrhosis. Methods: Seven Caucasian males with liver cirrhosis and seven healthy males matched for age (54.4±3.2 vs 54.6±4.4 years) and body mass index (25.3±1.2 vs 25.9±1.3kg/m2) were studied. Blood samples were drawn at 0, 30, 60, 90, 120, 150, and 180 min for determination of serum total and free IGF-I, IGFBP-1, IGFBP-2, and binary complex, while bioactive IGF-I was measured at 0, 30, 60, 120, and 180 min. Results: In comparison with healthy subjects, baseline levels of total (47%), free (36%), and bioactive IGF-I (51%) were lower, while IGFBP-1 (268%) was higher (P0.05), and the binary complex unchanged (∼100%) in cirrhotic patients. Serum total and free IGF-I, and IGFBP-2 remained unchanged in both study groups during the OGTT. Bioactive IGF-I decreased by 29% from baseline to 60 min in cirrhotic patients and remained low at the end of the OGTT (P

Original languageEnglish
Pages (from-to)285-292
Number of pages8
JournalEuropean Journal of Endocrinology
Volume155
Issue number2
DOIs
Publication statusPublished - Aug 2006

ASJC Scopus subject areas

  • Endocrinology

Fingerprint

Dive into the research topics of 'Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis'. Together they form a unique fingerprint.

Cite this